Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for microstomia in scleroderma
NCT04523506Phase 1Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- May 2020
- Primary completion
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of botulinum toxin type A in microstomia, sponsored by UT Southwestern Medical Center. Primary endpoint: Inter-labial distance at 3 months. Started May 2020; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
microstomia
Beyond the preview
Go deeper on NCT04523506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04523506.